• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Tokman Alexander Y

    2/23/24 5:00:32 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NDRA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Tokman Alexander Y

    (Last) (First) (Middle)
    3600 GREEN COURT, SUITE 350

    (Street)
    ANN ARBOR MI 48105

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ENDRA Life Sciences Inc. [ NDRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/02/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options $1.59 01/02/2024 A 600(1) (2) 01/02/2034 Common Stock 600 $0.00 600 D
    Explanation of Responses:
    1. Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy.
    2. This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025.
    Remarks:
    /s/ Alexander Y. Tokman by Mark Busch, attorney-in-fact 02/23/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NDRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NDRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NDRA
    Leadership Updates

    Live Leadership Updates

    See more
    • ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

      ANN ARBOR, MI / ACCESSWIRE / June 15, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer. In this new position, Ms. Pestrikova will assume all day-to-day responsibilities previously performed by ENDRA's Chief Financial Officer David Wells, who will leave the Company effective June 18, 2021 to pursue another opportunity.Ms. Pestrikova has supported ENDRA since 2014 and has been actively involved in ENDRA's financial planning and analysis, accounting and SEC reporting functions. Previously, Ms. Pestrikova was a financial analyst at a

      6/15/21 8:35:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to play an integral role in the treatment of metabolic disease. With a sharpened mission to transform the way steatotic liver disease (SLD) is diagnosed and managed, ENDRA is developing a revolutionary, low-cost, point-of-care diagnostic device—essentially a "blood pressure cuff" for the liver. This strategic shift is aimed squarel

      5/15/25 4:05:00 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

      Enhanced strategic focus for TAEUS addresses a large, unmet global need for a cost-effective tool for monitoring liver health at the point of patient care ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies. ENDRA's management has thoroughly evaluated the Company's technical capabilities and go-to-market strategy for TAEUS Liver and dete

      3/31/25 8:05:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

      3/31/25 8:00:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    SEC Filings

    See more
    • ENDRA Life Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

      5/30/25 8:00:47 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by ENDRA Life Sciences Inc.

      10-Q - ENDRA Life Sciences Inc. (0001681682) (Filer)

      5/15/25 4:59:32 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

      5/15/25 4:58:00 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

      4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      9/5/24 3:28:10 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: New insider Ubs Group Ag claimed ownership of 146,012 shares (SEC Form 3)

      3/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      9/5/24 2:47:08 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

      4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      8/29/24 4:30:01 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ENDRA Life Sciences Inc.

      SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

      6/14/24 4:01:26 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by ENDRA Life Sciences Inc.

      SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

      6/14/24 8:00:02 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by ENDRA Life Sciences Inc.

      SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

      3/10/23 12:18:14 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Financials

    Live finance-specific insights

    See more
    • ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

      3/31/25 8:00:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC ("Nasdaq"). On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq's maintenance requirements for listing. "Now that we have regained compliance with Nasdaq's listing requirements, we can focus all our efforts on making progress on our new transformational business strategies, which we reviewed during our August 22nd conference call,

      11/22/24 8:00:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

      ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. The Company will file its quarterly report on form 10-Q with the SEC as regularly scheduled in the coming days. A press release summarizing its financial and operating results for the second quarter ending on June 30, 2024, will be issued on the day of the call. Participants are encouraged to pre-register

      8/13/24 4:05:00 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

      4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      9/5/24 3:28:10 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

      4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      8/29/24 4:30:01 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care